As always, it was a delight to speak with our Editor-in-Chief, Peter C Taylor (University of Oxford, Oxford, UK). In this interview, we discuss JAK inhibitors and RA-related pain alongside the findings from the FINCH Phase 3 RA clinical trial program of filgotinib. The abstract ‘Effect of Filgotinib on Pain in Patients with Rheumatoid Arthritis: Results from Phase 3 Clinical Trials’ (ABSTRACT NUMBER: 1201) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
Questions
1. What are the major unmet needs in terms of pain control in the treatment of rheumatoid arthritis? (0:06)
2. What is the rationale for the use of JAK inhibitors in the treatment of rheumatoid arthritis? (1:49)
3. Could you give us a brief overview of the FINCH clinical studies and the findings? (3.32)
4. Could you tell us about the post-hoc analysis of the FINCH studies data? (4:22)
5. How do you think these findings could impact clinical practice? (10:36)
Disclosures: Peter C Taylor reports receiving: Research grants from Celgene, Galapagos, Gilead and Lilly; and consultation fees from AbbVie, BMS, Biogen, Fresenius, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Nordic Pharma, Pfizer, Roche, Sanofi, and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of virtual ACR Convergence 2020.
